Pediatric IMID pts have 4 fold mortality. Danish population study of 11,581 pIMID (vs 99K controls), 1.37 million PYs F/U. Dx age 12.6 yrs; 152 pIMID deaths (vs 316) aHR=3.8. +6.9 deaths/100K PYs. Most for GI Dz/CA & lymphoproliferative dz https://t.co/JpGzusLXMH https://t.co/OMtB1z0RmG

Hyperpigmentation from Hydroxychloroquine. From 316 HCQ pts, 26% got hyperpigmentation; delayed onset of 12 mos (6–30mos) after median cum. dose of 108 g. Seen on face (602%), Legs (36%) & hands (20%). Daily sun exposure decrease in the incidence (P=0.02) https://t.co/365qcuIpWE https://t.co/cHO16kDtK3

Chikungunya arthritis Metanalysis & good full-read review - 8 studies showing chronic arthritis (CCA) in minority of infected;, polyarticular, looks like RA, few seropositive, few w/ erosions on imaging. CCA may be progressive w/ irreversible damage https://t.co/Da7bKtM6oC https://t.co/OGBbIiGAc5

CPPD in seronegative RA? Among 364 RA patients - 73% seropositive & 26% seronegative (n=96). Amongst latter, 18 pt (18.9%) met CPPD-disease criteria. CPPD+ pts were more likely to be older & have Hx of acute episodic arthritis https://t.co/XO0J6Adaa0 https://t.co/3ouUCPshoh

Dawn of CAR-T cell therapy in autoimmune diseases - A review article from the Chinese Medical Journal https://t.co/Qbort9Rsmh https://t.co/wWwTXkZiXj

BSR Guideline on Management of Sjogren’s Syndrome Sjögren disease (SD) is the most common of all autoimmune disease, yet little is know of its etiology and there are insufficent interventions for those affected with mucosal or systemic manifestations. https://t.co/M5fQ8lyZBS https://t.co/30XpP3r4FV

AbbVie announced preliminary positive results from phase 3 SELECT-GCA study showing remission in 46% of #GCA pts Rx w/ upadacitinib for 52wks (vs 29% PBO); RCT included a 26-wk steroid taper regimen https://t.co/DIstJ4hazo https://t.co/VXc7rj0REJ

Renal Dz in 44 AOSD (Stills)pts-mean age 38; 28 w/ renal onset after Dx. 36 renal Bx showed amyloidosis (25%), collapsing glomerulopathy (11%), thrombotic microangiopathy (11%), IgA nephropathy (9%), minimal change (7%). Renal assoc w/ 6 deaths; 4 ESRD https://t.co/tQykmjNIIb https://t.co/n0xgi6uF6D

What a racket! Pharmacy benefit managers make billions collecting fees from payers & rebates from Pharma. 2022, these 3 (CVS Caremark, Express Scripts, OptumRx) control 79% of PBM market.Why is Congress dragging their feet here? Overview read from Reuters https://t.co/m5AnMFtEhf https://t.co/m5EwfcNMdo

GPA Management in 2024 https://t.co/qTwI7oVMBI https://t.co/Tr0eVmcgNN

Practice Metrics Use by Rheumatologists in RA. 54% of Rheums do "some" measure, Most used: HAQ 36%, RAPID3 27%, CDAI 18%, Vectra 13%. More than 35% do NOT measure https://t.co/FOlyCSFF25 https://t.co/3S36tDlgcE

TNFi mAbs, JAKi, –IL-17 are protective against Anterior Uveitis (AU) in AxSpA. Metanalysis of 44 RCTs shows AU IR: - TNF mAbs: 4.1 - etanercept 5.4 - IL-17i: 2.8 - JAKi: 1.5 - placebo: 10.8 https://t.co/qN9UL16YPO https://t.co/5WOjAq9ty6